The Role of Molecular and Cytogenetic Testing in Secondary AML

Author(s):

Margaret T. Kasner, MD,Christian Fidler, MD

Panelists discuss how comprehensive molecular and cytogenetic testing at diagnosis is crucial for accurate risk stratification, treatment selection, and prognostication in secondary acute myeloid leukemia (AML), while acknowledging the challenges of obtaining timely results, especially in community settings.

EP: 1.Implementing Updates to AML Classification Guidelines

EP: 2.Treatment Goals in Secondary AML

Now Viewing

EP: 3.The Role of Molecular and Cytogenetic Testing in Secondary AML

EP: 4.Patient-Centered Decision-Making in Secondary AML Treatment

EP: 5.Assessing Transplant Eligibility and Fitness for Intensive Chemotherapy

EP: 6.Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

EP: 7.Navigating Intensive Chemotherapy in the Community Setting

EP: 8.Optimizing AML Care Through Academic-Community Collaboration

EP: 9.Practice Pearls for Treatment of Secondary AML in the Community Setting

Video content above is prompted by the following:

Please discuss the importance of molecular and cytogenetic testing at diagnosis.
- Please highlight typical turnaround time in getting these results.
- Describe how the test results impact disease management.
What challenges are often faced in the community setting when it comes to getting molecular and cytogenetic test results in a timely manner?
- How do you handle situations when you are waiting for molecular test results?
- In which scenarios do you initiate treatment while awaiting results?